TFF3 and cancer: In conclusion, we have demonstrated highly significant and frequent cancer-specific promoter hypomethylation of TFF3 in malignant compared to non-malignant prostate tissue samples in two large independent RP cohorts, including a total of 789 PC and 94 NM tissue samples.